Clinical Intelligence

Quest Diagnostics launches opioid therapy genetic test

Monday, August 12, 2013 04:23 PM

Quest Diagnostics, a provider of diagnostic information services, has launched a lab-developed genetic test to aid the delivery of personalized opioid pain-relieving treatment. It is the first clinical lab to offer testing for variants in all cytochrome P450 (CYP450) genes known to influence the CYP450 enzyme system, which affects metabolism of opioids and other medications.

More... »

Catabasis announces successful phase I trial

Friday, August 9, 2013 02:09 PM

Catabasis Pharmaceuticals has announced preliminary data from a phase I trial of CAT-2003, an oral SMART Linker conjugate constructed using the company's proprietary technology, demonstrated a significant reduction in fasting and post-prandial triglyceride levels. CAT-2003 also had positive effects on other biomarkers, including reductions in apolipoprotein C-III (ApoC-III), a negative regulator of lipoprotein lipase, and apolipoprotein B (ApoB), the lipoprotein associated with VLDL and LDL cholesterol. In addition, reductions in plasma PCSK9 levels and LDL cholesterol were observed.

More... »

Boehringer, Lilly enroll first patient in type 2 diabetes trial

Friday, August 9, 2013 02:07 PM

Boehringer Ingelheim Pharmaceuticals and Eli Lilly have announced enrollment of the first patient into a cardiovascular (CV) and renal outcomes trial for linagliptin (tradjenta) tablets.

More... »

Aeterna Zentaris announces first patient dosed in phase III endometrial cancer trial

Friday, August 9, 2013 02:05 PM

Aeterna Zentaris has announced the first patient has been recruited and dosed for the phase III ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) trial in women with endometrial cancer resistant to platinum/taxane-based chemotherapy.

More... »

S1 Biopharma doses first patients in phase IIa trial of Lorexys

Tuesday, August 6, 2013 12:30 PM

S1 Biopharma, a developer of first-in-class drugs for sexual dysfunction in women and men, has announced enrollment and dosing of premenopausal women with hypoactive sexual desire disorder (HSDD) in the phase IIa clinical trial of its leading drug candidate Lorexys (S1P-104).

More... »

OncoGenex’s Spruce trial open for enrollment

Tuesday, August 6, 2013 10:30 AM

OncoGenex Pharmaceuticals has initiated the Spruce clinical trial, an investigator-sponsored, randomized, double-blind, placebo-controlled phase II trial evaluating OGX-427, a heat shock protein 27 (Hsp27) inhibitor, in patients with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC).

More... »

Spanish Myeloma Group study a treatment milestone

Monday, August 5, 2013 12:09 PM

Early treatment of asymptomatic myeloma, which has a high risk of developing into active multiple myeloma, can significantly improve the course of the disease, delay progression and increase patient survival. These were the conclusions of a clinical trial carried out by the Spanish Myeloma Group (GEM-PETHEMA), which unites specialists from more than 80 Spanish hospitals, published in the August issue of The New England Journal of Medicine.

More... »

The CenterWatch Monthly, August 2013

Friday, August 2, 2013 10:36 AM

Will end-to-end outsourcing take hold?

More... »

NeuroSigma set to commence phase III trial

Tuesday, July 30, 2013 11:33 AM

NeuroSigma, a Los Angeles-based medical device company, has announced conditional approval by the FDA of its IDE application to commence a phase III trial of the Monarch eTNS System for treatment of drug resistant epilepsy. The company is planning to conduct a multi-center trial at medical institutions in the U.S., Europe and Canada.  The objective of the study is to evaluate the safety and effectiveness of the device and provide the basis for a Pre-Market Approval (PMA) application to the FDA.

More... »

InspireMD announces first patient enrolled in MGuard trial

Tuesday, July 30, 2013 10:30 AM

InspireMD, an embolic protection stents company, has enrolled its first patient in the Master II IDE clinical trial to evaluate the safety and effectiveness of the MGuard Prime Embolic Protection Stent (EPS) in patients suffering from ST Elevation Myocardial Infarction (STEMI).

More... »